首页 | 本学科首页   官方微博 | 高级检索  
     

阿仑膦酸钠和阿法骨化醇联合治疗严重骨质流失和骨质疏松性骨折
引用本文:刘 锋,张 君,王文修,张明强,张志峰,侯海涛. 阿仑膦酸钠和阿法骨化醇联合治疗严重骨质流失和骨质疏松性骨折[J]. 中国组织工程研究, 2012, 16(39): 7395-7399. DOI: 10.3969/j.issn.2095-4344.2012.39.035
作者姓名:刘 锋  张 君  王文修  张明强  张志峰  侯海涛
作者单位:1河南省长垣县人民医院骨科,河南省长垣市 4534002新乡医学院第一附属医院骨科,河南省卫辉市 453100
摘    要:背景:阿仑膦酸钠和阿法骨化醇均可抑制骨质疏松性骨折患者骨转换,增加骨矿物密度。目的:观察阿仑膦酸钠和阿法骨化醇联合治疗患有严重骨质流失和骨质疏松性骨折患者的效果。方法:纳入严重骨质流失和骨质疏松性骨折患者,进行阿仑膦酸钠和阿法骨化醇联合治疗2年。结果与结论:相比治疗前,阿仑膦酸钠和阿法骨化醇联合治疗后患者腰椎骨密度增加(P < 0.05),随后尿Ⅰ型胶原N末端肽水平和血清碱性磷酸酶活性减少(P < 0.05)。证实,阿仑膦酸钠和阿法骨化醇联合治疗患有严重的骨质流失和骨质疏松性骨折患者疗效好。

关 键 词:阿仑膦酸钠  阿法骨化醇  联合  骨质流失  骨质疏松性骨折  组织工程  
收稿时间:2012-05-02

Alendronate plus alfacalcidol for the treatment of severe bone loss and osteoporotic fractures
Liu Feng,Zhang Jun,Wang Wen-xiu,Zhang Ming-qiang,Zhang Zhi-feng,Hou Hai-tao. Alendronate plus alfacalcidol for the treatment of severe bone loss and osteoporotic fractures[J]. Chinese Journal of Tissue Engineering Research, 2012, 16(39): 7395-7399. DOI: 10.3969/j.issn.2095-4344.2012.39.035
Authors:Liu Feng  Zhang Jun  Wang Wen-xiu  Zhang Ming-qiang  Zhang Zhi-feng  Hou Hai-tao
Affiliation:1Department of Orthopedics, the People's Hospital of Changyuan, Changyuan 453400, Henan Province, China
2Department of Orthopedics, the First Affiliated Hospital of Xinxiang Medical College, Weihui 453100, Henan Province, China
Abstract:BACKGROUND:Alendronate and alfacalcidol can inhibit the bone transformation and increase bone mineral density of the patients with osteoporotic fractures.OBJECTIVE:To investigate the effect of alendronate plus alfacalcidol for the treatment of severe bone loss and osteoporotic fractures.METHODS:Patients with severe bone loss and osteoporotic fractures were selected, and then the patients were treated with alendronate plus alfacalcidol for 2 years.RESULTS AND CONCLUSION:Compared with before treatment, the lumbar spine bone density of the patients was increased after treated with alendronate plus alfacalcidol (P < 0.05) followed by urine of type Ⅰ collagen N-terminal peptide levels and serum alkaline phosphatase activity decreased (P < 0.05). It confirmed that the alendronate plus alfacalcidol has good effect for the treatment of severe bone loss and osteoporotic fracture patients.
Keywords:
点击此处可从《中国组织工程研究》浏览原始摘要信息
点击此处可从《中国组织工程研究》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号